Timothy C Barabe bought $206k of RNAC
director at Cartesian Therapeutics, Inc.. 30,000 shares at an average of $6.86, traded Dec 4, 2025, filed Dec 8, 2025.
Score components
- +15RoleDirector
- +12Trade size$206k at market
- +10Relative to holdingsHoldings up 123%
- +18Price context4% above the 52-week low; 73% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +15.5%, 3m +34.2%, 6m -12.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001453687-25-000132, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 4, 2025 | POpen-market purchase Common Stock | +30,000 | $6.86 | $206k | 54,366 | Dec 8, 2025 |
Related signals
Other insiders at Cartesian Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | Cartesian Therapeutics, Inc. | Carsten Brunn President and CEO | $162k 23,766 shares | -7% | |
| 45Moderate | Cartesian Therapeutics, Inc. | Blaine Davis Chief Financial Officer | $72k 10,591 shares | -8% | |
| 30Weak | Cartesian Therapeutics, Inc. | Milos Miljkovic Chief Medical Officer | $24k 3,573 shares | -6% | |
| 53Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.5M 149,075 shares | +2% | |
| 45Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.4M 89,863 shares | +1% | |
| 30Weak | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $366k 20,967 shares | +0% | |
| 54Moderate | Cartesian Therapeutics, Inc. | Carsten Brunn President and CEO | $290k 17,271 shares | -8% | |
| 48Moderate | Cartesian Therapeutics, Inc. | Blaine Davis Chief Financial Officer | $134k 7,989 shares | -8% | |
| 40Moderate | Cartesian Therapeutics, Inc. | Emily English Chief Operations Officer | $30k 1,797 shares | -4% | |
| 36Weak | Cartesian Therapeutics, Inc. | Christopher M Jewell Chief Scientific Officer | $43k 2,550 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.